- Influenza
- Vaccine Recommendations
Please summarize what’s new in the 2023–24 influenza vaccine recommendations.
Yearly influenza vaccination continues to be recommended for everyone age 6 months and older. All available influenza vaccines in the United States continue to be quadrivalent (containing two influenza A and two influenza B strains). The changes in the CDC’s published Advisory Committee on Immunization Practices (ACIP) recommendations for influenza vaccination in 2023–2024 are summarized below:
- The 2023–24 vaccines include a new influenza A(H1N1)pdm09 component and influenza B/Victoria lineage virus vaccine antigens
- ACIP affirmed that everyone age 6 months and older who has an egg allergy should receive influenza vaccine. Any influenza vaccine (egg based or non-egg based) that is otherwise appropriate for the recipient’s age and health status may be used. ACIP updated its recommendation to state that egg allergy alone necessitates no additional safety measures for influenza vaccination beyond those recommended for any recipient of any vaccine, regardless of severity of previous reaction to egg. All vaccines should be administered in settings in which personnel and equipment needed for rapid recognition and treatment of acute hypersensitivity reactions are available.
The current ACIP recommendations for influenza vaccination are available here:Â www.cdc.gov/mmwr/volumes/72/rr/pdfs/rr7202a1-H.pdf.